Introduction Oral anticoagulants (OACs) prevent stroke in patients with atrial fibrillation (AF).
Several factors may cause OAC switching. Objectives To examine the phenomenon of OAC …

Direct oral anticoagulants have been an increasingly used class of drugs in the setting of
nonvalvular atrial fibrillation, defying vitamin K antagonists' monopoly when it comes to …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

Background Lifelong oral anticoagulation is recommended in patients with atrial fibrillation
(AF) to prevent stroke. Over the last decade, multiple new oral anticoagulants (OACs) have …

Background Direct-acting oral anticoagulants (DOACs) were developed as an alternative to
warfarin to treat and prevent thromboembolism, including stroke prevention in non-valvular …

Background and aims The effects of direct oral anticoagulants (DOACs) in patients with non-
valvular atrial fibrillation (NVAF) and liver disease remain poorly understood. Our …

Introduction Real-world evidence on the effects of direct oral anticoagulants (DOACs) in
patients with cancer associated venous thromboembolism (VTE) is limited. Thus, our …

Introduction In randomized trials in atrial fibrillation (AF) patients on direct oral
anticoagulants (DOACs) have a lower risk of bleeding compared with warfarin. However …

Objective To explore methodological challenges when using real-world evidence (RWE) to
estimate comparative-effectiveness in the context of Health Technology Assessment of direct …

Direct oral anticoagulants are now recommended by major guidelines as first-choice agents
for both stroke prevention in non-valvular atrial fibrillation and treatment/prevention of …